Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

2026-03-26 - 12:10

Highlights advancement of first-in-class neuroprotective candidate targeting demyelination Read More